{
    "2018-01-08": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Cramer's lightning round: Mercadolibre is even better than eBay was",
                "features": {
                    "keywords": [
                        "Mercadolibre",
                        "eBay",
                        "better"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "e-commerce"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Galapagos Reports Topline Data From Osteoarthritis Study",
                "features": {
                    "keywords": [
                        "Galapagos",
                        "Osteoarthritis",
                        "Topline",
                        "Data"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Understanding AbbVie’s Positive Upadacitinib Data for Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Atopic Dermatitis",
                        "Positive Data"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "US STOCKS-Wall St new year rally pauses as healthcare, bank stocks weigh",
                "features": {
                    "keywords": [
                        "US Stocks",
                        "Wall St",
                        "rally",
                        "healthcare",
                        "bank stocks"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Why AbbVie’s Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Rheumatoid Arthritis",
                        "Strong Data"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Upadacitinib",
                        "Breakthrough Therapy",
                        "FDA",
                        "Atopic Dermatitis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "What Upadacitinib Did for AbbVie in 2017",
                "features": {
                    "keywords": [
                        "Upadacitinib",
                        "AbbVie",
                        "2017"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "This Is Expected to Boost AbbVie’s Growth Prospects",
                "features": {
                    "keywords": [
                        "Boost",
                        "Growth Prospects",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Why Humira Is Still a Solid Growth Driver for AbbVie in 2018",
                "features": {
                    "keywords": [
                        "Humira",
                        "Solid Growth Driver",
                        "AbbVie",
                        "2018"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "How Increasing Biologic Penetration Could Boost AbbVie’s Revenues",
                "features": {
                    "keywords": [
                        "Increasing Biologic Penetration",
                        "Boost",
                        "Revenues",
                        "AbbVie"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}